sunvozertinib
dizal pharmaceuticals
['sunvozertinib', 'sclc', 'lung', 'nsclc']
#asco23 lung orals ph ii wu-kong6 of sunvozertinib in egfr exon20ins+ nsclc - 97pts
- orr 61%, similar efficacy in near &amp; far loop exon20ins
- well tolerated, most common g3+ tox, raised cpk very promising; despite short follow up. looking forward to ph iii 
Professor of Medical Oncology @CancerCentreIre | Thoracic Oncologist | Immunotherapy & Immune toxicity | Adjunct faculty Johns Hopkins University